Aflibercept + Folfiri for Treatment of Metastatic Colorectal Cancer After Oxaliplatin Failure: 4Th Interim Safety Data from the Global Aflibercept Safety and Quality-Of-Life Program (Asqop/Afeqt Studies)
Giovanni Luca Frassineti, Roberto Bordonaro(Ospedale Garibaldi), Volker Heinemann(LMU Klinikum), Sandrine Brette, Chiara Zilocchi(Sanofi (Italy)), Anne Thomas(Leicester Royal Infirmary), Maria Di Bartolomeo(Fondazione IRCCS Istituto Nazionale dei Tumori), Alberto F. Sobrero(Ospedale Policlinico San Martino), Gérard Lledo(American Society of Clinical Oncology), Julien Taı̈eb(Hôpital Européen Georges-Pompidou)
Cited by 4
Related Papers
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2014|1.7k
Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2020|1.3k
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2018|1.3k
FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis
|The Lancet Oncology|2016|914